We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
Read MoreHide Full Article
Key Takeaways
BMY faces generic pressure on key drugs like Revlimid and Pomalyst, plus Medicare Part D headwinds.
New drugs like Reblozyl, Opdualag and Breyanzi are driving growth amid strong uptake and new approvals.
BMY trades at 7.34x forward earnings, below its average and the broader large-cap pharma industry.
Bristol Myers (BMY - Free Report) depends on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition.
Legacy Portfolio is adversely impacted due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect.
Sales of blood thinner medicine Eliquis were down 4% in the first quarter due to the impact of Medicare Part D redesign in the United States.
In such a scenario, the performance of new drugs is key to BMY’s growth. Thalassemia drug, Reblozyl, has put up a stellar performance, driven by strong growth in the first and second-line treatment of myelodysplastic syndromes (MDS)-associated anemia. The drug should contribute significantly in the coming decade.
Revenue growth has been good for the leading immuno-oncology drug Opdivo, driven primarily by volume growth. Sales of CAR T cell therapy, Breyanzi, also continue to gain traction from the approval of new indications and expanded manufacturing capacity. Camzyos has also witnessed strong global uptake in obstructive HCM.
BMY had earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy.
The approval broadens BMY’s portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY’s top line in the coming years.
Competition for BMY’s Key Drugs
Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space.
The immuno-oncology space is dominated by pharma giant Merck’s (MRK - Free Report) blockbuster drug Keytruda (pembrolizumab).
Keytruda is approved for several types of cancer and alone accounts for around 50% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
Pfizer (PFE - Free Report) is one of the largest and most successful drugmakers in the field of oncology. It has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer.
Last month, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. BMY is also trying to develop bispecific antibodies.
BMY’s Price Performance, Valuation and Estimates
Shares of Bristol Myers have lost 15% year to date compared with the industry’s decline of 3.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 7.34x forward earnings, lower than its mean of 8.54x and the large-cap pharma industry’s 14.79X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 and 2026 earnings per share has moved south in the past 60 days.
Image: Shutterstock
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
Key Takeaways
Bristol Myers (BMY - Free Report) depends on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition.
Legacy Portfolio is adversely impacted due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect.
Sales of blood thinner medicine Eliquis were down 4% in the first quarter due to the impact of Medicare Part D redesign in the United States.
In such a scenario, the performance of new drugs is key to BMY’s growth. Thalassemia drug, Reblozyl, has put up a stellar performance, driven by strong growth in the first and second-line treatment of myelodysplastic syndromes (MDS)-associated anemia. The drug should contribute significantly in the coming decade.
Revenue growth has been good for the leading immuno-oncology drug Opdivo, driven primarily by volume growth. Sales of CAR T cell therapy, Breyanzi, also continue to gain traction from the approval of new indications and expanded manufacturing capacity. Camzyos has also witnessed strong global uptake in obstructive HCM.
BMY had earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy.
The approval broadens BMY’s portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY’s top line in the coming years.
Competition for BMY’s Key Drugs
Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space.
The immuno-oncology space is dominated by pharma giant Merck’s (MRK - Free Report) blockbuster drug Keytruda (pembrolizumab).
Keytruda is approved for several types of cancer and alone accounts for around 50% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
Pfizer (PFE - Free Report) is one of the largest and most successful drugmakers in the field of oncology. It has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer.
Last month, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. BMY is also trying to develop bispecific antibodies.
BMY’s Price Performance, Valuation and Estimates
Shares of Bristol Myers have lost 15% year to date compared with the industry’s decline of 3.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 7.34x forward earnings, lower than its mean of 8.54x and the large-cap pharma industry’s 14.79X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 and 2026 earnings per share has moved south in the past 60 days.
Image Source: Zacks Investment Research
BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.